Αποτελέσματα αναζήτησης - "генетическая детерминация"

Πηγή: Vavilov Journal of Genetics and Breeding; Том 22, № 8 (2018); 1000-1008 ; Вавиловский журнал генетики и селекции; Том 22, № 8 (2018); 1000-1008 ; 2500-3259

Θεματικοί όροι: ионные каналы почки, regulation, hypertensive disease, low-renin hypertension, genetic determination, pathophysiology, aldosterone, renin, kidney ion channels, регуляция, гипертоническая болезнь, низкорениновая гипертония, генетическая детерминация, патофизиология, альдостерон, ренин

Περιγραφή αρχείου: application/pdf

Relation: https://vavilov.elpub.ru/jour/article/view/1802/1158; Åkerström T., Maharjan R., Willenberg H.S., Cupisti K., Ip J., Moser A., Stålberg P., Robinson B., Iwen K.A., Dralle H., Walz M.K., Lehnert H., Sidhu S., Gomez-Sanchez C., Hellman P., Björklund P. Activating mutations in CTNNB1 in aldosterone producing adenomas. Sci. Rep. 2016;6:19546. DOI 10.1161/01.HYP.8.2.93.; Antonov Y.V., Alexandrovich Y.V., Redina O.E., Gilinsky M.A., Markel A.L. Stress and hypertensive disease: adrenals as a link. Experimental study on hypertensive ISIAH rat strain. Clin. Exp. Hypertens. 2016;38(5):415-423. DOI 10.3109/10641963.2015.1116546.; Azizan E.A.B., Poulsen H., Tuluc P., Zhou J., Clausen M.V., Lieb A., Maniero C., Garg S., Bochukova E.G., Zhao W., Shaikh L.H., Brighton C.A., Teo A.E.D., Davenport A.P., Dekkers T., Tops B., Küsters B., Ceral J., Yeo G.S.H., Neogi S.G., McFarlane I., Rosenfeld N., Marass F., Hadfeld J., Margas W., Chaggar K., Solar M., Deinum J., Dolphin A.C., Farooqi I.S., Striessnig J., Nissen P., Brown M.J. Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension. Nat. Genet. 2013;45: 1055-1060. DOI 10.1038/ng.2716.; Boyden L.M., Choi M., Choate K.A., Nelson-Williams C.J., Farhi A., Toka H.R., Tikhonova I.R., Bjornson R., Mane S.M., Colussi G., Lebel M., Gordon R.D., Semmekrot B.A., Poujol A., Välimäki M.J., De Ferrari M.E., Sanjad S.A., Gutkin M., Karet F.E., Tucci J.R., Stockigt J.R., Keppler-Noreuil K.M., Porter C.C., Anand S.K., Whiteford M.L., Davis I.D., Dewar S.B., Bettinelli A., Fadrowski J.J., Belsha C.W., Hunley T.E., Nelson R.D., Trachtman H., Cole T.R.P., Pinsk M., Bockenhauer D., Shenoy M., Vaidyanathan P., Foreman J.W., Rasoulpour M., Thameem F., Al-Shahrouri H.Z., Radhakrishnan J., Gharavi A.G., Goilav B., Lifton R.P. Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities. Nature. 2012;482:98-102. DOI 10.1038/nature10814.; Calhoun D.A. Aldosteronism and hypertension. Clin. J. Am. Soc. Nephrol. 2006;1:1039-1045. DOI 10.2215/CJN.01060306.; Channick B.J., Adlin E.V., Marks A.D. Suppressed plasma renin activity in hypertension. Arch. Intern. Med. 1969;123:131-140. DOI 10.1001/archinte.1969.00300120019003.; Charles L., Triscott J., Dobbs B. Secondary hypertension: discovering the underlying cause. Am. Fam. Physician. 2017;96(7):453-461.; Choi M., Scholl U.I., Yue P., Björklund P., Zhao B., Nelson-Williams C., Ji W., Cho Y., Patel A., Men C.J., Lolis E., Wisgerhof M.V., Geller D.S., Mane S., Hellman P., Westin G., Åkerström G., Wang W., Carling T., Lifton R.P. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science. 2011;331(6018):768-772. DOI 10.1126/science.1198785.; Conn J.W. Evolution of primary aldosteronism as a highly specifc clinical entity. J. Am. Med. Assoc. 1960;172:1650-1653. DOI 10.1001/jama.1960.63020150008016.; Dahl L.K., Heine M., Tassinari L. Role of genetic factors in susceptibility to experimental hypertension due to chronic excess salt ingestion. Nature. 1962;194:480-482. DOI 10.1038/194480b0.; Elijovich F., Weinberger M.H., Anderson C.A.M., Appel L.J., Bursztyn M., Cook N.R., Dart R.A., Newton-Cheh C.H., Sacks F.M., Laffer C.L. On behalf of the American Heart Association Professional and Public Education Committee of the Council on Hypertension; Council on Genomic and Precision Medicine; and Stroke Council. Salt sensitivity of blood pressure: a scientifc statement from the American Heart Association. [published online ahead of print July 21, 2016]. Hypertension. DOI 10.1161/HYP.0000000000000047.; Fernandes-Rosa F.L., Daniil G., Orozco I.J., Göppner C., El Zein R., Jain V., Boulkroun S., Jeunemaitre X., Amar L., Lefebvre H., Schwarzmayr T., Strom T.M., Jentsch T.J., Zennaro M.-C. A gainof-function mutation in the CLCN2 chloride channel gene causes primary aldosteronism. Nat. Genet. 2018;50:355-361. DOI 10.1038/s41588-018-0053-8.; Fernandes-Rosa F.L., Williams T.A., Riester A., Steichen O., Beuschlein F., Boulkroun S., Strom T.M., Monticone S., Amar L., Meatchi T., Mantero F., Cicala M.-V., Quinkler M., Fallo F., Allolio B., Bernini G., Maccario M., Giacchetti G., Jeunemaitre X., Mulatero P., Reincke M., Zennaro M.-C. Genetic spectrum and clinical correlates of somatic mutations in aldosterone¬producing adenoma. Hypertension. 2014;64:354-361. DOI 10.1161/HYPERTENSIONAHA.114.03419.; Freel E.M., Connell J.M.C. Mechanisms of hypertension: the expanding role of aldosterone. J. Am. Soc. Nephrol. 2004;15(8):1993-2001. DOI 10.1097/01.ASN.0000132473.50966.14.; Funder J.W., Carey R.M., Mantero F., Murad M.H., Reincke M., Shibata H., Stowasser M., Young W.F. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 2016;101:1889-1916. DOI 10.1210/jc.2015-4061.; Geller D.S., Farhi A., Pinkerton N., Fradley M., Moritz M., Spitzer A., Meinke G., Tsai F.T., Sigler P.B., Lifton R.P. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science. 2000;289:119-123. DOI 10.1126/science.289.5476.119.; Geller D.S., Zhang J., Wisgerhof M.V., Shackleton C., Kashgarian M., Lifton R.P. A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism. J. Clin. Endocrinol. Metab. 2008;93:3117-3123. DOI 10.1210/jc.2008-0594.; Gianmichele G., O’Shaughenessy K., Murthy M. Role for germline mutations and a rare coding single nucleotide polymorphism within the KCNJ5 potassium channel in a large cohort of sporadic cases of primary aldosteronism. Hypertension. 2014;63:783-789. DOI 10.1016/j.clinthera.2014.05.058.; Gordon R.D. Syndrome of hypertension and hyperkalemia with normal glomerular fltration rate. Hypertension. 1986;8(2):93-102. DOI 10.1161/01.HYP.8.2.93.; Griffng G.T., Wilson T.E., Melby J.C. Alterations in aldosterone secretion and metabolism in low renin hypertension. J. Clin. Endocrinol. Metab. 1990;71:1454-1460. DOI 10.1210/jcem-71-6-1454.; Hanukoglu I., Hanukoglu A. Epithelial sodium channel (ENaC) family: phylogeny, structure-function, tissue distribution, and associated inherited diseases. Gene. 2016;579:95-132. DOI 10.1016/j.gene.2015.12.061.; Hypertension. Eds. E.L. Schiffrin, R.M. Touyz. London: Future Medicine, 2013.; Jacovic S., Zivkovic-Radojevic M., Petrovic D. Secondary hypertension: differential diagnosis and basic principles of treatment. Ser. J. Exp. Clin. Res. 2016;17(4):349-356. DOI 10.1515/SJECR_2015_0056.; Jose A., Crout J.R., Kaplan N.M. Suppressed plasma renin activity in essential hypertension. Roles of plasma volume, blood pressure, and sympathetic nervous system. Ann. Intern. Med. 1970;72:9-16. DOI 10.7326/0003-4819-72-1-9.; Kaplan N.M. Hypokalemia in the hypertensive patient: with observations on the incidence of primary aldosteronism. Ann. Intern. Med. 1967;66:1079-1090. DOI 10.7326/0003-4819-66-6-1079.; Liddle G.W., Bledsoe T., Coppage W.S.J. A familial renal disorder simulating primary aldosteronism but with negligible aldosterone secretion. Trans. Assoc. Am. Phys. 1963;76:199-213. NII Article ID (NAID): 10018198924. http://ci.nii.ac.jp/naid/10018198924/; Liu K., Qin F., Sun X., Zhang Y., Wang J., Wu Y., Ma W., Wang W., Wu X., Qin Y., Zhang H., Zhou X., Wu H., Hui R., Zou Y., Jiang X., Song L. Analysis of the genes involved in Mendelian forms of low-renin hypertension in Chinese early-onset hypertensive patients. J. Hypertens. 2018;36:502-509. DOI 10.1097/HJH.0000000000001556.; Louis-Dit-Picard H., Barc J., Trujillano D., Miserey-Lenkei S., Bouatia-Naji N., Pylypenko O., Beaurain G., Bonnefond A., Sand O., Simian C., Vidal-Petiot E., Soukaseum C., Mandet C., Broux F., Chabre O., Delahousse M., Esnault V., Fiquet B., Houillier P., Bagnis C.I., Koenig J., Konrad M., Landais P., Mourani C., Niaudet P., Probst V., Thauvin C., Unwin R.J., Soroka S.D., Ehret G., Ossowski S., Caulfeld M., International Consortium for Blood Pressure (ICBP), Bruneval P., Estivill X., Froguel P., Hadchouel J., Schott J.-J., Jeunemaitre X. KLHL3 mutations cause familial hyperkalemic hypertension by impairing ion transport in the distal nephron. Nat. Genet. 2012;44:S1-S3. DOI 10.1038/ng.2218.; MacConnachie A.A., Kelly K.F., McNamara A., Loughlin S., Gates L.J., Inglis G.C., Jamieson A., Connell J.M., Haites N.E. Rapid diagnosis and identifcation of cross-over sites in patients with glucocorticoid remediable aldosteronism. J. Clin. Endocrinol. Metab. 1998;83:4328-4331. DOI 10.1210/jcem.83.12.5309.; Markou A., Sertedaki A., Kaltsas G., Androulakis I.I., Marakaki C., Pappa T., Gouli A., Papanastasiou L., Fountoulakis S., Zacharoulis A., Karavidas A., Ragkou D., Charmandari E., Chrousos G.P., Piaditis G.P. Stress-induced aldosterone hyper-secretion in a substantial subset of patients with essential hypertension. J. Clin. Endocrinol. Metab. 2015;100:2857-2864. DOI 10.1210/jc.2015-1268.; Mishra S., Ingole S., Jain R. Salt sensitivity and its implication in clinical practice. Indian Heart J. 2018:70(4):556-564. DOI 10.1016/j.ihj.2017.10.006.; Monticone S., Burrello J., Tizzani D., Bertello C., Viola A., Buffolo F., Gabetti L., Mengozzi G., Williams T.A., Rabbia F., Veglio F., Mulatero P. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J. Am. Coll. Cardiol. 2017a;69(14):1812-1820. DOI 10.1016/j.jacc.2017.01.052.; Monticone S., D’Ascenzo F., Moretti C., Williams T.A., Veglio F., Gaita F., Mulatero P. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta¬analysis. Lancet Diabetes Endocrinol. 2018a;6:41-50. DOI 10.1016/S2213-8587(17)30319-4.; Monticone S., Else T., Mulatero P., Williams T.A., Rainey W.E. Understanding primary aldosteronism: impact of next generation sequencing and expression profling. Mol. Cell Endocrinol. 2015a;399:311- 320. DOI 10.1016/j.mce.2014.09.015.; Monticone S., Losano I., Tetti M., Buffolo F., Veglio F., Mulatero P. Diagnostic approach to low-renin hypertension. Clin. Endocrinol. 2018b;1-12. DOI 10.1111/cen.13741.; Monticone S., Tetti M., Burrello J., Buffolo F., De Giovanni R., Veglio F., Williams T.A., Mulatero P. Familial hyperaldosteronism type III. J. Hum. Hypertens. 2017b;31:776-781. DOI 10.1038/jhh.2017.34.; Monticone S., Viola A., Rossato D., Veglio F., Reincke M., GomezSanchez C., Mulatero P. Adrenal vein sampling in primary aldoste- ronism: towards a standardised protocol. Lancet Diabetes Endocrinol. 2015b;3:296-303. DOI 10.1016/S2213-8587(14)70069-5.; Mulatero P., Milan A., Fallo F., Regolisti G., Pizzolo F., Fardella C., Mosso L., Marafetti L., Veglio F., Maccario M. Comparison of confrmatory tests for the diagnosis of primary aldosteronism. J. Clin. Endocrinol. Metab. 2006;91:2618-2623. DOI 10.1210/jc.2006-0078.; Mulatero P., Monticone S., Bertello C., Viola A., Tizzani D., Iannaccone A., Crudo V., Burrello J., Milan A., Rabbia F., Veglio F. Longterm cardio¬ and cerebrovascular events in patients with primary aldosteronism. J. Clin. Endocrinol. Metab. 2013;98:4826-4833. DOI 10.1210/jc.2013-2805.; Mulatero P., Rabbia F., Milan A., Paglieri C., Morello F., Chiandussi L., Veglio F. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension. 2002;40:897-902. DOI 10.1016/S0895-7061(03)00766-0.; Mulatero P., Verhovez A., Morello F., Veglio F. Diagnosis and treatment of low-renin hypertension. Clin. Endocrinol. (Oxf). 2007;67:324- 334. DOI 10.1111/j.1365-2265.2007.02898.x.; New M.I., Geller D.S., Fallo F., Wilson R.C. Monogenic low renin hypertension. Trends Endocrinol. Metab. 2005;16:92-97. DOI 10.1016/j.tem.2005.02.011.; Rafestin-Oblin M.E., Souque A., Bocchi B., Pinon G., Fagart J., Vandewalle A. The severe form of hypertension caused by the activating S810L mutation in the mineralocorticoid receptor is cortisone related. Endocrinology. 2003;144:528-533. DOI 10.1210/en.2002-220708.; Rapp J.P., Dene H. Development and characteristics of inbred strains of Dahl salt-sensitive and salt-resistant rats. Hypertension. 1985;7(1): 340-349.; Sagnella G.A. Why is plasma renin activity lower in populations of African origin? J. Hum. Hypertens. 2001;15:17-25.; Salti I.S., Stiefel M., Ruse J.L., Laidlaw J.C. Non-tumorous “primary” aldosteronism. I. Type relieved by glucocorticoid (glucocorticoidremediable aldosteronism. Can. Med. Assoc. J. 1969;101:1-10.; Scholl U.I., Goh G., Stölting G., de Oliveira R.C., Choi M., Overton J.D., Fonseca A.L., Korah R., Starker L.F., Kunstman J.W., Prasad M.L., Hartung E.A., Mauras N., Benson M.R., Brady T., Shapiro J.R., Loring E., Nelson-Williams C., Libutti S.K., Mane S., Hellman P., Westin G., Åkerström G., Björklund P., Carling T., Fahlke C., Hidalgo P., Lifton R.P. Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. Nat. Genet. 2013;45:1050-1054. DOI 10.1038/ng.2695.; Scholl U.I., Healy J.M., Thiel A., Fonseca A.L., Brown T.C., Kunstman J.W., Horne M.J., Dietrich D., Riemer J., Kücükköylü S., Reimer E.N., Reis A.C., Goh G., Kristiansen G., Mahajan A., Korah R., Lifton R.P., Prasad M.L., Carling T. Novel somatic mutations in primary hyperaldosteronism are related to the clinical, radiological and pathological phenotype. Clin. Endocrinol. 2015a;83:779-789. DOI 10.1111/cen.12873. Epub 2015 Sep 23.; Scholl U.I., Stölting G., Nelson-Williams C., Vichot A.A., Choi M., Loring E., Prasad M.L., Goh G., Carling T., Juhlin C.C., Quack I., Rump L.C., Thiel A., Lande M., Frazier B.G., Rasoulpour M., Bowlin D.L., Sethna C.B., Trachtman H., Fahlke C., Lifton R.P. Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism. Elife. 2015b;4:e06315. DOI 10.7554/eLife.06315.; Scholl U.I., Stölting G., Schewe J., Thiel A., Tan H., Nelson-Williams C., Vichot A.A., Jin S.C., Loring E., Untiet V. , Yoo T., Choi J., Xu S., Wu A., Kirchner M., Mertins P., Rump L.C., Onder A.M., Gamble C., McKenney D., Lash R.W., Jones D.P., Chune G., Gagliardi P., Choi M., Gordon R., Stowasser M., Fahlke C., Lifton R.P. CLCN2 chloride channel mutations in familial hyperaldosteronism type II. Nat. Genet. 2018;50(3):349-354. DOI 10.1038/s41588-018-0048-5.; Song Y., Yang S., He W., Hu J., Cheng Q., Wang Y., Luo T., Ma L., Zhen Q., Zhang S., Mei M., Wang Z., Qing H., Bruemmer D., Peng B., Li Q. Chongqing Primary Aldosteronism Study (CONPASS) Group. Confrmatory tests for the diagnosis of primary aldosteronism: a prospective diagnostic accuracy study. Hypertension. 2018;71(1):118- 124. DOI 10.1161/HYPERTENSIONAHA.117.10197.; Sutherland D.J., Ruse J.L., Laidlaw J.C. Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Can. Med. Assoc. J. 1966;95:1109-1119.; Tetti M., Monticone S., Burrello J., Matarazzo P., Veglio F., Pasini B., Jeunemaitre X., Mulatero P. Liddle syndrome: review of the literature and description of a new case. Int. J. Mol. Sci. 2018;19(3):E812. DOI 10.3390/ijms19030812.; Vilela L.A.P., Almeida M.Q. Diagnosis and management of primary aldosteronism. Arch. Endocrinol. Metab. 2017;61(3):305-312. DOI 10.1590/2359-3997000000274.; Wang J.J., Peng K.Y., Wu V.C., Tseng F.Y., Wu K.D. CTNNB1 mutation in aldosterone producing adenoma. Endocrinol. Metab. (Seoul). 2017;32:332¬338. DOI 10.3803/EnM.2017.32.3.332.; Wang L.P., Yang K.Q., Jiang X.J., Wu H.Y., Zhang H.M., Zou Y.B., Song L., Bian J., Hui R.T., Liu Y.X., Zhou X.L. Prevalence of Liddle syndrome among young hypertension patients of undetermined cause in a chinese population. J. Clin. Hypertens. (Greenwich). 2015;17:902-907. DOI 10.1111/jch.12598.; Weinberger M.H. Salt sensitivity of blood pressure in humans. Hypertension. 1996;27:481-490.; Williams T.A., Lenders J.W.M., Mulatero P., Burrello J., Rottenkolber M., Adolf C., Satoh F., Amar L., Quinkler M., Deinum J., Beuschlein F., Kitamoto K.K., Pham U., Morimoto R., Umakoshi H., Prejbisz A., Kocjan T., Naruse M., Stowasser M., Nishikawa T., Young W.F. Jr, Gomez-Sanchez C.E., Funder J.W., Reincke M.; Primary Aldosteronism Surgery Outcome (PASO) investigators. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol. 2017;5(9):689-699. DOI 10.1016/S2213-8587(17)30135-3.; Wilson F.H., Disse-Nicodème S., Choate K., Ishikawa K., NelsonWilliams C., Desitter I., Gunel M., Milford D.V., Lipkin G.W., Achard J.M., Feely M.P., Dussol B., Berland Y., Unwin R.J., Mayan H., Simon D.B., Farfel Z., Jeunemaitre X., Lifton R.P. Human hypertension caused by mutations in WNK kinases. Science. 2001;293(5532):1107-1112. DOI 10.1126/science.1062844.; Wilson R.C., Dave-Sharma S., Wei J.Q., Obeyesekere V.R., Li K., Ferrari P., Krozowski Z.S., Shackleton C.H.L., Bradlow L., Wiens T., New M.I. A genetic defect resulting in mild low-renin hypertension. Proc. Natl. Acad. Sci. USA. 1998;95:10200-10205.; Yagil C., Katni G., Rubattu S., Stolpe C., Kreutz R., Lindpaintner K., Ganten D., Ben-Ishay D., Yagil Y. Development, genotype and phenotype of a new colony of the Sabra hypertension prone (SBH/y) and resistant (SBN/y) rat model of salt sensitivity and resistance. J. Hypertens. 1996;14:1175-1182.; Yau M., Haider S., Khattab A., Ling C., Mathew M., Zaidi S., Bloch M., Patel M., Ewert S., Abdullah W., Toygar A., Mudryi V., Al Badi M., Alzubdi M., Wilson R.C., Al Azkawi H.S., Ozdemir H.N., AbuAmer W., Hertecant J., Razzaghy-Azar M., Funder J.W., Al Senani A., Sun L., Kim S.-M., Yuen T., Zaidi M., New M.I. Clinical, genetic, and structural basis of apparent mineralocorticoid excess due to 11β-hydroxysteroid dehydrogenase type 2 defciency. Proc. Natl. Acad. Sci. USA. 2017;114:E11248-E11256. DOI 10.1073/pnas.1716621115.; https://vavilov.elpub.ru/jour/article/view/1802

Διαθεσιμότητα: https://vavilov.elpub.ru/jour/article/view/1802
https://doi.org/10.18699/VJ18.443

View record from BASE

5

Academic Journal